Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05030155
Other study ID # D20180135
Secondary ID 2020-003318-10
Status Recruiting
Phase Phase 3
First received
Last updated
Start date May 30, 2022
Est. completion date May 2025

Study information

Verified date October 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Benjamin TERRIER, MD, PhD
Phone (+33)1 58 41 14 61
Email benjamin.terrier@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.


Description:

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome, is a rare systemic small-vessel vasculitis, associated with asthma and blood and tissue eosinophilia. EGPA belongs to the group of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), and commonly involves upper and lower respiratory tracts, the lungs, the peripheral nerve and the heart. Therapeutic management is based on glucocorticoids alone or in combination with conventional immunosuppressive agents, mainly azathioprine, methotrexate or cyclophosphamide, according to disease severity assessed by the Five Factor Score. Such treatments, in addition to their common side effects, are frequently insufficiently effective to control chronic asthma and/or rhinosinusitis, requiring long-term high-dose corticosteroids. Because EGPA shares common pathophysiological features with eosinophilic disorders and asthma, new therapeutic options used in these conditions could be of interest, in particular mepolizumab, a monoclonal anti-interleukin (IL)-5 antibody, which has shown promising results in two small preliminary studies to control disease activity and decrease glucocorticoids in cortico-dependant patients. In addition, mepolizumab has been recently evaluated in a prospective trial, the MIRRA trial, targeting a small niche of patients, i.e. those with corticodependent asthma unable to achieve disease control with low dose of glucocorticoids. Results published revealed that mepolizumab led to significantly more accrued weeks of remission than placebo (28% vs. 3% of the participants had ≥24 weeks of accrued remission; odds ratio, 5.91; 95% confidence interval [CI], 2.68 to 13.03; P<0.001) and a higher percentage of participants in remission at both week 36 and week 48 (32% vs. 3%; odds ratio, 16.74; 95% CI, 3.61 to 77.56; P<0.001). However, these studies did not evaluate the interest of mepolizumab during EGPA flare associating asthma, eosinophilic and vasculitis lesions, in order to induce remission of the disease and rapidly decrease and discontinue glucocorticoids. Also, recent pathophysiological date strongly support in addition to previous therapeutic studies the major interest to target IL-5 as soon as EGPA is diagnosed: 1) genetic association studies demonstrated that polymorphisms in the IL-5 pathway are associated with EGPA in comparison with controls, 2) increased expression of IL-5 in mice model are able to induce vasculitis lesions as observed in the human diseases. Patients will receive a standardized glucocorticoid tapering schedule. From day 28 post-baseline onwards, if the subject's BVAS=0 their oral prednisone dose should be tapered downwards. A standardized glucocorticoid tapering schedule provided in the protocol enables a reduction in oral prednisone dose every 2 weeks, with the intention of achieving a prednisone dose of 4 mg/day or less. Once a subject has achieved a dose of 4 mg/day prednisone, the investigator is encouraged to continue tapering downwards, if clinically warranted, at dose increments of 1.0 mg every week. Upwards dose adjustments within the 0-4.0 mg range are permitted without necessarily being considered a relapse.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with a diagnosis of EGPA independently of ANCA status, - Patients aged of 18 years or older, - Patients with newly-diagnosed disease or relapsing disease at the time of screening, with an active disease defined as a Birmingham Vasculitis Activity Score (BVAS) =3, - Patients within the first 21 days following initiation/increase of corticosteroids at a dose = 1 mg/kg/day (pulses of methylprednisolone before oral corticosteroid therapy are authorized) - Patients having given their written informed consent prior to participation in the study. - Patients affiliated with social security or CMU (profit or being entitled) Exclusion Criteria: - Patients with GPA, MPA, or other vasculitis, defined by the ACR criteria and/or the Chapel Hill Consensus Conference, - Patients with vasculitis in remission of the disease defined as a BVAS <3 - Patients with severe cardiac failure defined as class IV in New York Heart Association - Patients with acute infections or chronic active infections (including HIV, HBV or HCV and checked in the last 12 months), - Patients with active cancer or recent cancer (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment, - Pregnant women and lactation. Patients with childbearing potential should have reliable contraception for the 12 months duration of the study, - Patients with EGPA who have already been treated with mepolizumab within the previous 12 months, - Patients with hypersensitivity to a monoclonal antibody or biologic agent, - Patients with contraindication to use mepolizumab, cyclophosphamide, mesna, azathioprine or maintenance therapy used for vasculitis, - Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol, - Patients included in other investigational therapeutic study within the previous 3 months, - Patients suspected not to be observant to the proposed treatments, - Patients who have white blood cell count =4,000/mm3, - Patients who have platelet count =100,000/mm3, - Patients who have ALT or AST level greater that 3 times the upper limit of normal that cannot be attributed to underlying EGPA disease, - Patients unable to give written informed consent prior to participation in the study - Patients under tutorship or curatorship and protected adults.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mepolizumab
300 mg/month subcutaneous
cyclophosphamide/azathioprine
Patients with FFS=1 will receive cyclophosphamide then azathioprine
Placebo
Patients with FFS=0 will receive placebo

Locations

Country Name City State
France Service de Médecine Interne, Centre de référence " Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques "Hôpital Cochin Paris

Sponsors (3)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris French Vasculitis Study Group, URC-CIC Paris Descartes Necker Cochin

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients who achieved a prednisone dose of 4.0 mg or less per day at day 168, without experiencing a relapse EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) active vasculitis (BVAS >0); OR b) active asthma symptoms; OR c) active nasal and/or sinus disease, warranting: i) an increased dose of prednisone compared to previous dosage and at least >4 mg/day prednisone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalisation related to EGPA worsening. A BVAS evaluation will be conducted at the time of a relapse, or as soon as possible afterwards Day 168
Secondary Prednisone dosage at days 168 and 364 Days 168 and 364
Secondary Area under the curve for corticosteroids at days 168 and 364 Days 168 and 364
Secondary Proportion of participants with a prednisone dose of 4.0 mg or less per day for 0 weeks Days 168 and 364
Secondary Proportion of participants with a prednisone dose of 4.0 mg or less per day for more than 0 weeks but less than 4 weeks Days 168 and 364
Secondary Proportion of participants with a prednisone dose of 4.0 mg or less per day for more than 4 weeks but less than 12 weeks Days 168 and 364
Secondary Proportion of participants with a prednisone dose of 4.0 mg or less per day for at least 12 weeks Days 168 and 364
Secondary Proportion of participants with a prednisone dose of 4.0 mg or less per day at both days 168 and 364. Day 364
Secondary Proportion of participants experiencing a relapse EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) active vasculitis (BVAS >0); OR b) active asthma symptoms; OR c) active nasal and/or sinus disease, warranting: i) an increased dose of prednisone compared to previous dosage and at least >4 mg/day prednisone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalisation related to EGPA worsening. A BVAS evaluation will be conducted at the time of a relapse, or as soon as possible afterwards Day 364
Secondary Number of relapse during the study period EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) active vasculitis (BVAS >0); OR b) active asthma symptoms; OR c) active nasal and/or sinus disease, warranting: i) an increased dose of prednisone compared to previous dosage and at least >4 mg/day prednisone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalisation related to EGPA worsening. A BVAS evaluation will be conducted at the time of a relapse, or as soon as possible afterwards. Day 364
Secondary Time from inclusion to first relapse Day 364
Secondary Number of adverse events that result in the cessation of further injections Number of adverse events is expressed as adverse events according to the CTCAE toxicity grading system per patient-year at days 168 and 364 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorraghic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, injection reactions (within 24 hours of injection). Day 364
Secondary Vasculitis Damage Index (VDI) Days 168 and 364
Secondary HAQ questionnaire Days 168 and 364
Secondary SF-36 questionnaire Days 168 and 364
Secondary Evolution of ANCA titers (in UI/mL) and correlation with clinical events during follow-up Day 364
Secondary Evolution of eosinophils (in x10^9/L) and correlation with clinical events during follow-up Day 364
See also
  Status Clinical Trial Phase
Recruiting NCT02967068 - VCRC Tissue Repository
Recruiting NCT05979051 - A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA) Phase 2/Phase 3
Active, not recruiting NCT03164473 - Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Phase 3
Recruiting NCT05263934 - Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Phase 3
Recruiting NCT02006134 - Pediatric Vasculitis Initiative
Recruiting NCT06046222 - Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis Phase 2
Completed NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Not yet recruiting NCT06231498 - The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis
Recruiting NCT00315380 - Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Completed NCT03298061 - Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Phase 3